Literature DB >> 27725317

Timing of dental development in osteogenesis imperfecta patients with and without bisphosphonate treatment.

Ilkka Vuorimies1, Heidi Arponen2, Helena Valta3, Outi Tiesalo2, Marja Ekholm2, Helena Ranta4, Marjut Evälahti2, Outi Mäkitie5, Janna Waltimo-Sirén6.   

Abstract

Bisphosphonates have established their role as medical therapy for pediatric osteogenesis imperfecta (OI) patients. Since bisphosphonates have also been shown to delay tooth development in animal models, we aimed to assess whether the medication has a similar effect on children with OI. In this cross-sectional study, bisphosphonate-treated OI patients of whom dental panoramic tomograph was taken between 3 and 16years of age formed the study group. The patients, 22 in total, had been treated with pamidronate, zoledronic acid or risedronate for at least one year before the radiography. Developmental stage of the permanent teeth, resorption of the deciduous teeth, and number of the erupted permanent teeth were radiographically assessed in the left mandibular quadrant. Dental panoramic tomographs of 50 OI patients, naïve to bisphosphonates, and of 50 healthy individuals of the same age were used as controls. The dental development was statistically significantly accelerated in the OI group naïve to bisphosphonates showing median advancement of dental age by 0.63years from chronological age and median increase in the number of erupted teeth by 0.31 as compared to Finnish norms. Bisphosphonate-treated OI patients displayed, however, age-appropriate dental development. The OI patients not treated with bisphosphonates also showed statistically significantly faster resorption of the deciduous teeth than the treated ones, and displayed an altered interrelationship between the resorption stage of an individual primary tooth and the developmental stage of the succedaneous permanent tooth, unlike the OI patients treated with bisphosphonate. No correlation between either cumulative bisphosphonate dose or between treatment length and any measured component of the dental development was found. To conclude, OI itself was found to lead to advanced dental development. Bisphosphonate treatment had a delaying effect in all the three aspects studied, resulting in a rate of dental development indistinguishable from normal. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bisphosphonate; Fracture; Osteoclast; Pediatrics; Pharmacology

Mesh:

Substances:

Year:  2016        PMID: 27725317     DOI: 10.1016/j.bone.2016.10.004

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  8 in total

Review 1.  Zoledronic acid in pediatric metabolic bone disorders.

Authors:  Sasigarn A Bowden; John D Mahan
Journal:  Transl Pediatr       Date:  2017-10

Review 2.  Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.

Authors:  A Biggin; C F Munns
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

3.  Challenges of delivery of dental care and dental pathologies in children and young people with osteogenesis imperfecta.

Authors:  R Clark; C P Burren; R John
Journal:  Eur Arch Paediatr Dent       Date:  2019-03-13

4.  Computed Tomography-Based Investigation on the Effects of Intravenous Bisphosphonate Administration on Tooth Growth in a Minipig Animal Model.

Authors:  Philipp Poxleitner; Pit J Voss; David Steybe; Lisa-Marie Seibert; Stephan Zeiter; Martin J Stoddart; Rainer Schmelzeisen; Sven Otto
Journal:  Medicina (Kaunas)       Date:  2022-06-09       Impact factor: 2.948

5.  Bisphosphonate Therapy and Tooth Development in Children and Adolescents with Osteogenesis Imperfecta.

Authors:  Barbro Malmgren; Georgios Tsilingaridis; Nina Monsef-Johansson; Zaina Haif Al Qahtani; Göran Dahllöf; Eva Åström
Journal:  Calcif Tissue Int       Date:  2020-05-25       Impact factor: 4.333

6.  Pamidronate decreases bilirubin-impaired cell death and improves dentinogenic dysfunction of stem cells from human deciduous teeth.

Authors:  Haruyoshi Yamaza; Soichiro Sonoda; Kazuaki Nonaka; Toshio Kukita; Takayoshi Yamaza
Journal:  Stem Cell Res Ther       Date:  2018-11-08       Impact factor: 6.832

Review 7.  Osteogenesis Imperfecta: New Perspectives From Clinical and Translational Research.

Authors:  Josephine T Tauer; Marie-Eve Robinson; Frank Rauch
Journal:  JBMR Plus       Date:  2019-02-20

8.  Dental phenotype in an adolescent with osteogenesis imperfecta type XII.

Authors:  Joanna Yuet-Ling Tung; Jeni Lai-In Ho; Ricky Wong; Siu-Chung Fung
Journal:  BMJ Case Rep       Date:  2022-04-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.